TriSalus Life Sciences, Inc. (TLSI)

Market Cap	288.64M
Revenue (ttm)	18.51M
Net Income (ttm)	-59.04M
Shares Out	30.10M
EPS (ttm)	-6.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,597
Open	9.45
Previous Close	9.37
Day's Range	9.31 - 9.60
52-Week Range	3.32 - 12.83
Beta	0.65
Analysts	n/a
Price Target	n/a
Earnings Date	May 15, 2024

About TLSI

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced panc...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 112
• Stock Exchange: NASDAQ
• Ticker Symbol: TLSI

Financial Performance

In 2023, TLSI's revenue was $18.51 million, an increase of 49.31% compared to the previous year's $12.40 million. Losses were -$59.04 million, 25.1% more than in 2022.